Company Description
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system.
The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders.
Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes.
The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases.
Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2024 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| CEO | Jonathan Violin |
Contact Details
Address: 221 Crescent Street, Building 23 Waltham, Massachusetts 02453 United States | |
| Phone | (781) 516-2325 |
| Website | korsana.com |
Stock Details
| Ticker Symbol | KRSA |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CUSIP Number | 23255M303 |
| ISIN Number | US23255M3034 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan Violin M.B.A., Ph.D. | President, Chief Executive Officer, Secretary and Director |
| Dr. Mark Joseph Vignola Ph.D. | Chief Financial Officer |
| Dr. Gan Wei Ph.D. | Chief Technical Officer |
| Madelyn Demsky Zeylikman | General Counsel |
| Dr. Matthew Leoni M.D. | Chief Medical Officer |
| Kyle Breidenstine CPA, M.B.A. | Senior Vice President of Finance and Treasurer |